IrinaAzaryanMD

PubMed

• Indolent behavior of malignant Bethesda III nodules compared to Bethesda V/VI nodules.
  Peng, J., Brock, P., Endo, M., Nabhan, F., Azaryan, I., Long, C., Ryan, L., Ringel, M., Sipos, J.> ;The Journal of Clinical Endocrinology and Metabolism. 2024 Feb 28
• Ultrasound Features and Performance of Afirma Gene Sequencing Classifier in Cytologically Indeterminate Thyroid Nodules.
  Ma, J., Peng, J., Azaryan, I., Endo, M., Sipos, J., Nabhan, F.> ;Journal of the Endocrine Society. 2024 Jan 16
• 3 citations
  Effect of the COVID-19 pandemic on surgery for indeterminate thyroid nodules (THYCOVID): a retrospective, international, multicentre, cross-sectional study.
  Fabio Medas, Chiara Dobrinja, Ebtesam Abdullah Al-Suhaimi, Julia Altmeier, Said Anajar, Akif Enes Arikan, Irina Azaryan, Lovenish Bains, Giancarlo Basili, Hakan Bolukb...> ;The Lancet. Diabetes & Endocrinology. 2023 Jun 1
• 5 citations
  Features of Cytologically Indeterminate Molecularly Benign Nodules Treated With Surgery.
  Mayumi Endo, Kyle Porter, Clarine Long, Irina Azaryan, John E. Phay, Matthew D. Ringel, Jennifer A. Sipos, Fadi Nabhan> ;The Journal of Clinical Endocrinology and Metabolism. 2020 Nov 1
• 66 citations
  Afirma Gene Sequencing Classifier Compared with Gene Expression Classifier in Indeterminate Thyroid Nodules.
  Mayumi Endo, Fadi Nabhan, Kyle Porter, Katie Roll, Lawrence A. Shirley, Irina Azaryan, Dena Tonkovich, Jeanette Perlick, Laura E. Ryan, Raheela Khawaja, Shumei Meng, J...> ;Thyroid. 2019 Aug 19
• Join now to see all